NL-OMON41740已完成4 期
The effect of Ivacaftor in CF patients with a class III mutation - TICTAC II study
niversitair Medisch Centrum Utrecht0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 2 至 99（—）
入选标准
- •CFTR genotype associated with residual CFTR function;
- •Already had a rectal biopsy to produce an organoid;
- •Start a treatment with Ivacaftor;
- •Male and female patients, aged 6 years or older on the date of informed consent;
- •Signed informed consent form (IC), and where appropriate, signed assent form.
排除标准
- •Use of curcumin and or genistein at start or within two weeks prior to start of the study;
- •Inability to follow instructions of the investigator.
研究者
相似试验
已完成
不适用
The effect of Ivacaftor in CF patients with a class III mutatioNL-OMON26309niversity Medical Center Utrecht (UMCU)10
已完成
不适用
Ivacaftor in French Patients With Cystic Fibrosis and a G551D MutationCystic FibrosisNCT02194881Assistance Publique - Hôpitaux de Paris57
已完成
2 期
Safety Study of Ivacaftor in Subjects With Cystic FibrosisCystic FibrosisNCT00457821Vertex Pharmaceuticals Incorporated39
已完成
不适用
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controlsmucoviscoidosis10083624Cystic fibrosisNL-OMON46971HagaZiekenhuis12
进行中（未招募）
1 期
The influence of cytochrome P450 3A4 inhibitors on serum levels of Ivacaftor in cystic fibrosis patients and healthy subjects.cystic fibrosis and healthy subjectsEUCTR2016-001440-18-NLuniversity medical center utrecht12